Skye Bioscience Faces Investor Lawsuit Following Clinical Trial Setback

Shares of biotechnology firm Skye Bioscience are experiencing significant turmoil. The company is now confronting a class action lawsuit filed by investors, compounding the pressure from disappointing clinical trial results for its lead drug candidate announced last fall. The legal action alleges the company made misleading statements and inflated expectations.

Financial and Legal Fallout Intensifies

The legal firm Faruqi & Faruqi, LLP has initiated a nationwide class action investigation against Skye Bioscience and formally filed suit. The complaint centers on accusations that the company issued materially misleading business statements and failed to disclose that its drug candidate, Nimacimab, was less effective than investors had been led to believe. This alleged misrepresentation is said to have overstated the drug’s clinical, regulatory, and commercial prospects. Investors seeking to be a lead plaintiff in the case have until January 16, 2026, to step forward.

This lawsuit follows a dramatic decline in the company’s stock value. Currently trading at $1.19, the share price reflects a steep drop from its previous close of $2.55. During the trading session, shares moved between $1.05 and $1.20. Over the past 52 weeks, the equity has been highly volatile, reaching a low of $1.04 and a high of $5.75.

Disappointing Data Triggered the Decline

The catalyst for the current crisis was an October 6, 2025, announcement. On that date, Skye Bioscience released topline results from its 26-week Phase 2a “CBeyond™” study evaluating Nimacimab. The outcomes were mixed. The monotherapy arm of the trial failed to meet its primary endpoint of weight reduction compared to a placebo. A preliminary analysis also suggested lower-than-expected drug concentration levels in the body, potentially necessitating higher dosages.

The market’s reaction was swift and severe. The stock plummeted by $2.85 per share, representing a single-day loss of 60 percent, and closed at $1.90.

Should investors sell immediately? Or is it worth buying Skye Bioscience?

A Glimmer of Hope in Combination Therapy

Despite the monotherapy setback, the clinical trial did reveal a potentially promising pathway. Data from the combination therapy arm showed more encouraging results. According to the company, 100 percent of patients receiving the combination treatment achieved weight loss exceeding five percent. This compares to 85 percent of patients treated solely with Novo Nordisk’s Wegovy. Furthermore, 67 percent of combination therapy patients lost over ten percent of their body weight, versus 50 percent in the Wegovy-only group.

In response, Skye Bioscience plans to advance Nimacimab into a Phase 2b combination study. The company also intends to investigate higher monotherapy doses within this next trial phase. Additional data from these efforts are expected in 2026.

Financial Health Under Scrutiny

The company’s latest financial statements highlight ongoing challenges. For the third quarter of 2025, Skye Bioscience reported a net loss of $12.8 million. Its research and development expenses nearly doubled year-over-year, reaching $9.4 million. The firm’s cash and equivalents position was reported at $35.3 million.

The coming months are critical for Skye Bioscience. The company must navigate the dual challenges of advancing its clinical program while managing legal proceedings and working to restore investor confidence. The resolution of the class action suit and the forthcoming clinical data in 2026 are poised to determine its future trajectory.